Matthew's practice focuses on life sciences and other technology-driven enterprises, including emerging biotech and medical device companies. With this industry focus, Matthew advises issuers, investors and dealers in public and private corporate finance transactions such as venture capital financings, private placements and public offerings, including IPOs.
Matthew also advises acquirers and targets undertaking public or private M&A transactions including share acquisitions, plans of arrangement and other business combinations. Matthew provides ongoing advice on Canadian corporate and securities laws to clients ranging from established public issuers to technology start-ups. Matthew also advises clients on commercial agreements including IP licensing transactions, distribution arrangements and research and collaboration agreements.